CME Supplements

The Clinical Conundrum in Managing Preterm Birth: Balancing Historical Trial Results, Society Guidelines, and Clinical Experience with a Contradictory Trial Outcome

This activity is supported by an independent educational grant from AMAG Pharmaceuticals, Inc.


Since its approval in 2011, 17-alpha hydroxyprogesterone caproate (17-OHPC, trade name Makena®, AMAG Pharmaceuticals, Inc, Waltham, MA) has been designated the “standard of care “ for treating pregnant patients with a history of spontaneous preterm birth (SPTB) by the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal Fetal Medicine (SMFM), and the American College of Nurse Midwives (ACNM). Several clinical trials and years of clinical experience have demonstrated its safety and efficacy.

This CME supplement details results of the PROLONG (Progestin’s Role in Optimizing Neonatal Gestation) trial evaluating 17-OHPC in patients with a history of a prior spontaneous singleton preterm delivery.

Click Here to Read More

To receive CME credit, please
read the article and go to
to access the posttest and evaluation.

Recommended Reading

Progesterone supplementation does not PROLONG pregnancy in women at risk for preterm birth: What do we do now?
MDedge ObGyn
US rates of preterm birth
MDedge ObGyn
2020 Update on obstetrics
MDedge ObGyn
Cognitive problems after extremely preterm birth persist
MDedge ObGyn
Infant deaths from birth defects decline, but some disparities widen
MDedge ObGyn